- The two-day virtual event to be held from April 22-23 is focused on driving collaborative partnerships to enhance the drug development ecosystem through the art of deal-making
- The summit is designed to provide insight into M&A, an attractive option for MedTech and pharmaceutical companies experiencing complex R&D, patent expirations and other impediments to growth
- 20+ knowledgeable, esteemed speakers will grace the stage
Companies view mergers and acquisitions (“M&A”) as opportunities to broaden their portfolio, expand to international markets and increase leverage and scale. In the MedTech industry, in particular, companies look at M&A as an opportunity to drive positive financial growth and enhance therapeutic solutions (https://ibn.fm/yqmb6), as well as to address industry changes such as those brought by newly introduced regulations, slowed health care spending, negative pricing trends or, more recently, the pandemic.
While the importance of M&A cannot be understated, ultimate success can only be realized if the entire process is flawless from beginning to end. Thus, sharp focus is required when searching for and evaluating potential targets for M&A and during the subsequent negotiations to reach a mutually beneficial agreement.
Dynamic Global Events (“DGE”), the organizers of the Biopharma BD&L Summit to be held from April 22 to 23, understand these very facts. This is why the event, to be held virtually, will provide an unmatched deep-dive into partnership strategies, licensing priorities and how to avoid possible pitfalls at different stages of the M&A process. On top of this, the event will offer networking opportunities.
With the pandemic having slowed down research and development (“R&D”), not to mention the introduction of new regulations in the biomedical/MedTech industry that increase the cost of R&D and lower R&D productivity, M&A as a solution to these issues needed now more than ever. It is a cost-effective, faster, and more efficient alternative to the in-house development of solutions. However, the possibility of making mistakes at different stages of the process means that the event has come at a very opportune time.
The Biopharma BD&L Summit will provide insight into new paradigms for external innovations, discuss critical evaluation methods from a small company perspective and offer information on the proven approaches for maximizing intellectual property (“IP”) due diligence. Additionally, attendees will learn strategic and tactical considerations for negotiating a term sheet, as well as how the reimbursement environment impacts the deal-making landscape.
Summit highlights include a Fireside Chat with Nigel Sheail, Global Head, Mergers & Acquisitions and Business Development & Licensing, Novartis, and Patrick Amstutz, CEO, Molecular Partners, focusing on mitigating the risks associated with an accelerated deal. A dynamic panel including Jeffrey Warmke, Senior Vice President, Global Business Development, Daiichi Sankyo, Steve Twait, Vice President, Alliance and Integration Management, AstraZeneca, and Mark Coflin, Vice President, Head Global Alliance Management, Simcere, discusses win-win opportunities for expanding successful partnerships or creating additional spin-off collaborations.
The Biopharma BD&L Summit is ideal for various professionals who deal with mergers and acquisitions either directly or indirectly. It is focused on driving collaborative partnerships to enhance the drug development ecosystem through smart and savvy deal-making, that is, the art of deal-making.
For more information about the event and to register, visit https://dgevents.com/event/biopharma-bdl-summit/
To receive a discount on your registration, use code IBN2021.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.